Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Declines By 45.2%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 37,100 shares, a decline of 45.2% from the December 15th total of 67,700 shares. Based on an average trading volume of 307,000 shares, the short-interest ratio is presently 0.1 days. Currently, 2.8% of the shares of the company are short sold.

Sonoma Pharmaceuticals Trading Up 1.5 %

Sonoma Pharmaceuticals stock traded up $0.04 during trading on Thursday, reaching $2.66. The company had a trading volume of 53,750 shares, compared to its average volume of 43,035. The firm has a market capitalization of $3.56 million, a price-to-earnings ratio of -0.53 and a beta of 1.41. The firm’s 50-day simple moving average is $2.73 and its 200 day simple moving average is $2.12. Sonoma Pharmaceuticals has a 52 week low of $2.44 and a 52 week high of $9.37.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.